INITIAL RESULTS OF THE RE-VERSE AD TRIAL: IDARUCIZUMAB REVERSES THE ANTICOAGULANT EFFECTS OF DABIGATRAN IN PATIENTS IN AN EMERGENCY SETTING OF MAJOR BLEEDING, URGENT SURGERY OR INTERVENTIONSCharles V. Pollack, CW Kam, Stephan Glund et al.|Emergency Medicine Journal|2015Cited by 7
Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventionsCharles V. Pollack, Jeffrey I. Weitz, Paul Reilly et al.|Journal of Thrombosis and Haemostasis|2015Cited by 2